Webinars » Cost Reduction Strategies in Clinical Stage Process Optimization for Biologics

Cost Reduction Strategies in Clinical Stage Process Optimization for Biologics

    Rubin Jiang
  • Speaker:Rubin Jiang, Director of Antibody Process Development & MSAT, GenScript ProBio
  • Date: May 14 th, 2024
  • Time: 14:00-15:00 (GMT+8)

Speaker Biography

Rubin Jiang, Director of Antibody Process Development & MSAT, received his Master's degree in Biotechnology from Northeastern University in 2014. In the same year, he worked at Sanofi-Genzyme as a process engineer for upstream process development of antibodies and recombinant proteins. From 2014 to 2020, he worked in the process development department of Merck Sharp & Dohme as a researcher and senior researcher, responsible for the upstream process development, process characterization and validation, as well as leading the upstream process development of Merck Sharp & Dohme's continuous production and process on-line analysis (PAT) upstream development. During this period, he participated in the publication of 7 academic articles. From mid-2020 to 2022, he worked in Hangzhou Yi'an Jishi as Deputy Director and Director, responsible for upstream process development department, in charge of CDMO upstream process development, and also promoted and enhanced fed-batch process and continuous perfusion process platform.

Topic Background

Costly medicines are a burden for both individual patients and national budgets. The Prescription Drug Law within the Inflation Reduction Act (IRA) exemplifies efforts to make medicines more affordable. The production of biologics requires intricate manufacturing processes within a highly regulated environment, leading to high production expenses. Greater control over the production costs of biologics has emerged as a pivotal factor for drug manufacturers to uphold competitiveness in the biopharmaceutical industry. Taking monoclonal antibody products as an example, this webinar focuses on reducing the commercial production costs of biopharmaceuticals.

Topic Abstract

  • The timeline of late-stage processes development
  • Factors in the reduction of cost of goods (COGs) per unit of DS.

    • Upstream productivity

    • Production scale

    • Raw material

Related service:

2000L GMP Drug Substance Manufacturing-GenScript ProBio